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ABSTRACT   
 
Background: Cannabinoid-based medicines (CBMs) are being used widely in the elderly.  
However, their safety and tolerability in older adults remains unclear. We aimed to conduct a 
systematic review and meta- analysis of safety and tolerability of cannabinoid-based 
medicines (CBMs) in adults of age ≥50 years. 
 
Methods and findings: 
A systematic search was performed using MEDLINE, PubMed, EMBASE, CINAHL 
PsychInfo, Cochrane Library and ClinicalTrials.gov (1st Jan 1990 to 31st Oct 2020). 
Randomised clinical trials (RCTs) of CBMs in those with mean age of ≥50 years for all 
indications, evaluating the safety/tolerability of CBMs where adverse events have been 
quantified were included. Study quality was assessed using the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) criteria and Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were 
followed. Two reviewers conducted all review stages independently. Where possible, data 
were pooled using random-effects meta-analysis. Effect sizes were calculated as incident 
rate ratio (IRR) for outcome data such as AEs, SAEs and death and risk ratio (RR) for 
withdrawal from study and reported separately for studies using THC, THC:CBD 
combination and CBD. 46 RCTs were identified as suitable for inclusion of which 31 (67%) 
were conducted in the UK and Europe. There were 6216 patients (mean age 58.6± 7.5 
years; 51% male) included in the analysis, with 3469 receiving CBMs. Compared with 
controls, delta-9-tetrahydrocannabinol (THC)-containing CBMs significantly increased the 
incidence of all-cause and treatment-related Adverse Events (AEs): THC alone (IRR:1.42 
[95% CI,1.12 -1.78]) and (IRR: 1.60 [95% CI, 1.26 -2.04]); THC: cannabidiol (CBD) 
combination (IRR:1.58 [95% CI,1.26 -1.98]) and (IRR:1.70 [95% CI,1.24 -2.33]) respectively. 
IRRs of Serious AEs (SAEs) and deaths were not significantly greater under CBMs 
containing THC with or without CBD. THC:CBD combination (RR:1.40 [95% CI,1.08 -1.80]) 
but not THC alone (RR:1.18 [95% CI,0.89 -1.57]) significantly increased risk of AE-related 
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withdrawals. CBD alone did not increase the incidence of all-cause AEs (IRR: 1.02 [95% 
CI,0.90 -1.16]) or other outcomes as per qualitative synthesis. AE-related withdrawals were 
significantly associated with THC dose in THC only [QM (df= 1)= 4.696, p=0.03] and 
THC:CBD combination treatment ([QM (df=1)=4.554, p=0.033]. THC-containing CBMs 
significantly increased incidence of dry mouth, dizziness/ light-headedness and 
somnolence/drowsiness. Study limitations include inability to fully exclude data from those   
< 50 years age in our primary analyses as well as limitations related to weaknesses in the 
included trials particularly incomplete reporting of outcomes and heterogeneity in included 
studies.  
 
Conclusions: This pooled analysis, using data from RCTs with mean participant age ≥ 50 
years, suggests that although THC-containing CBMs are associated with side-effects, CBMs 
in general are safe and acceptable in older adults. However, THC:CBD combinations may 
be less acceptable in the dose ranges used and their tolerability may be different in adults 















Why was this study done? 
• Use of cannabinoid-based medicines (CBMs) has been growing steadily in recent 
years, including in the elderly. However, their safety and tolerability in older adults 
remains unclear.  
• With increasing interest in the use of CBMs in older people and growing unlicensed 
use, there is a particular need to examine their safety and tolerability in older adults. 
• We analysed data on safety and tolerability from previously published double-blind, 
randomized controlled trials (RCT) using delta-9-tetrahydorcannabinol (THC) and 
cannabidiol (CBD) the common constituents of most CBMs, alone or in combination, 
to examine their effect on older adults. 
What did the researchers do and find? 
• We pooled data from 46 published RCTs (with information from 6216 patients; with 
mean participant age ≥ 50 years) on adverse events, serious adverse events or 
death, and withdrawal from study. We also examined the relationship between the 
dose of THC used in THC-containing CBMs and the incidence of adverse 
consequences in older adults. 
• Our results suggest that compared with the control condition, treatment with THC-
containing CBMs was associated on average with significantly greater incidence of 
all cause and treatment-related adverse events.  
• There was no significant increase in the incidence of serious adverse events or death 
with any CBMs. The risk of withdrawal from study was increased only in those 
receiving THC:CBD combination treatment, and this was related to THC dose. 
What do these findings mean? 
• These findings suggest that CBMs in general are safe and acceptable in older adults. 
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• Our findings that THC-containing CBMs are associated with side-effects and that 
THC:CBD combinations may be less acceptable at the dose ranges typically used in 























The cannabis plant (CANNABIS SATIVA L.) has been used worldwide both for recreational 
and medicinal purposes for thousands of years. With a fast-growing aging population, its 
medicinal use has also caught up and is growing in the elderly [1-3]. 
 
Among the cannabinoids found in the cannabis plant, delta-9-tetrahydorcannabinol (THC) 
and cannabidiol (CBD) are the most well-characterised and often considered for medicinal 
purposes. THC can cause intoxication [4,5]  and has anti-emetic, analgesic and potentially 
neuroprotective and anti-inflammatory effects. On the other hand, CBD is non- intoxicating 
[5,6] with antiepileptic and potentially also anti-inflammatory, neuroprotective, antioxidant 
and antipsychotic effects [7-9]. While several trials have used these cannabinoids for a wide 
range of diseases and indications, a majority of these have investigated younger people 
[10,11]. However, age-related pharmacodynamic and pharmacokinetic changes as well as 
higher prevalence of co-morbidities and polypharmacy in the elderly mean that they may 
have a different profile of safety and tolerability to cannabinoids [12,13] compared to younger 
people, as is well-known with other groups of medications especially those used for 
disorders of the central nervous system [14]. Both THC and CBD, the common constituents 
of most cannabinoid-based medicines in current use have prominent effects on brain 
function and cognition [15]. Therefore, evidence of safety and tolerability of cannabinoid-
based medicines (CBM) established in studies in younger adults cannot be directly 
extrapolated to the older adults. Although, a number of recent reviews and meta-analyses 
[12,16,17] have summarized the safety and tolerability profile of CBMs, they have all pooled 
data from studies investigating across the age spectrum, making it difficult to draw age-
specific inferences. With increasing interest in their use in disorders typically affecting older 
people [18-20] and growing unlicensed use [21], there is a particular need to investigate the 
safety and tolerability of CBMs in older people. This is also relevant, as there is a widely held 
view that many of the naturally derived cannabinoids are generally safe as they have been 
around and used for a long time. 
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Here, we have addressed this by investigating the safety and tolerability of CBMs in people 
over 50 years of age through systematically reviewing all double-blind, randomized 
controlled trials (RCT) using CBMs that focused on people with mean age of 50 years and 
over to conduct a meta-analysis. As there is a larger evidence base of studies with mean 
age of participants ³ 50 years than the more limited set of studies that have exclusively 
focused on people over 50 years and even less on people over 65 or 75 years, we have 
focused on studies with mean age of participants ³ 50 years and complemented these 
results with additional analyses restricted to studies that have exclusively focused on people 
over 50 years and even less on people over 65. Existing meta-analytic investigations [16,17] 
have generally considered all CBMs together, irrespective of whether they included THC, 
CBD or THC:CBD in combination. However, THC can cause intoxication and may induce 
anxiety and transient psychotomimetic effects [5], especially at higher doses and in 
vulnerable individuals, while CBD does not cause intoxication when directly compared in the 
same individuals [5] and may potentially ameliorate anxiety and psychosis [9,22-24]. Further, 
there is growing evidence that THC and CBD may have opposing acute effects on 
autonomic arousal, brain [15] and cardiovascular function [25,26] and CBD may mitigate 
some of the harmful effects of THC on cognition and behaviour [15,27,28], consistent with 
their opposing effects on some of their molecular targets [4]. This suggests that THC and 
CBD may have distinct tolerability profiles, with the possibility that certain side-effects may 
be noticeable in those taking formulations containing only THC, but not in those taking 
formulations containing only CBD while adverse effects may even be mitigated in those 
taking THC and CBD in combination. This underscores the importance of examining their 
safety and tolerability separately. Therefore, we have addressed this issue by separately 
investigating the effects of THC, CBD or THC:CBD in combination.  
 
We hypothesized that compared to control treatments all 3 categories of CBMs will be 
associated with: i) a greater incidence of adverse events (AEs); ii) no greater incidence of 
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serious adverse events (SAEs) or death; and iii) no greater risk of withdrawal from study. 
Further, we hypothesized a direct relationship between the dose of THC used in THC-
containing CBMs and the incidence of adverse consequences in older adults. 
 
METHODS 
Data sources and searches 
The review was undertaken according to the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) reporting guidelines [29] (see S1 PRISMA checklist). 
The study protocol was pre-registered with the International Prospective Register of 
Systematic Reviews (PROSPERO) (CRD42019148869). Ethics approval was not required 
for this systematic review and meta-analysis. 
A detailed description of the bibliographic search strategy is presented in Methods in S2 
appendix. We identified studies published from Jan 1, 1990 up to 31st Oct 2020, from several 
electronic databases. Studies were independently assessed by 2 researchers and 
disagreements resolved through consensus or discussions with a third researcher. 
 
Study selection 
Studies were included if (1) published from 1990 onwards; (2) included older adults (defined 
as mean age ≥50 years) or reported a distinct subgroup of older adults and provided 
separate results for this subgroup; and (3) provided data on the safety and tolerability of 
medical cannabinoids administered by any route, at any dose, for any duration and for any 
indication. Studies were excluded if they (1) included exclusively younger subjects (mean 
age <50 years); (2) studied effects of cannabinoids for recreational purposes or failed to 
provide the dosage of cannabinoids; and (3) were not reported in English language. Here we 
focus on results from randomised controlled trials (RCTs). 
Data extraction and quality assessment 
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All relevant available data for examination of the safety and tolerability of different CBMs 
(THC:CBD combination or THC or CBD alone) was collected from eligible studies, 
complemented with information from ClinicalTrials.gov and author responses. 
Data was extracted for study design, participant characteristics, indication, dosage and 
duration of intervention, all cause and treatment-related AEs and SAEs, AE-related 
withdrawals and deaths. 
 
AEs and SAEs were coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA) ‘system organ classes’ (SOC). Data was also extracted for the top 5 (as reported 
by each study) AEs for each SOC, where available. Data extraction and coding was verified 
by a medically qualified researcher and discrepancies resolved following discussions with 
senior researcher. The disease conditions investigated were classified into broader 
subgroups for analysis purpose.  
Overall quality of evidence was assessed using recommended criteria [30] and summarised 
to reflect confidence in estimates [31].  
 
Data synthesis and analysis 
Total exposure to active intervention in person-years was estimated by first calculating this 
for each individual study by multiplying the number of subjects in the active intervention arm 
with the duration of treatment for that arm for each study and then adding up these study-
specific values for all studies under each broad category (THC, THC:CBD or CBD) of 
intervention investigated here. Mean exposure in person-years for each category (THC, 
THC:CBD or CBD) of intervention was estimated by calculating the arithmetic mean from 
study-specific estimates obtained as above for each intervention category. Pooled mean 
ages of participants for each group of studies and treatment arms were estimated by 
calculating the arithmetic mean of study specific mean age as reported by individual studies 
for each intervention arm. Other pooled estimates (median and interquartile range) for 
summary study characteristics , such as, duration of study in weeks, participants analysed or 
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included, or duration of treatment for each treatment arm (as reported in Table 1 in S2 
Appendix), were calculated by estimating them from the total number (e.g. for variables such 
as number of participants included or analysed; duration of study  or treatment) or the mean 
estimate (e.g. for variables such as mean age) as reported in individual studies for each set 
sub groups of RCTs.  
 
Pooled effect-sizes were estimated if there were 2 or more RCTs within each group or sub-
group under the random-effects model using the restricted maximum-likelihood estimator 
because of anticipated heterogeneity. For each broad category of intervention, analyses 
combined both parallel-arm and crossover RCTs, with the latter treated as parallel-arm 
design [32] for pooled analyses. But we also report results by RCT design for each 
intervention. We estimated incident rate ratio (IRR) for outcome data such as AEs, SAEs 
and death and risk ratio (RR) for withdrawal from study. Studies with more than one active 
treatment arm were treated as independent studies. In studies with more than one active 
treatment arm compared against a single control group we also report meta-analysis of 
dependent effect-sizes with robust variance estimation [33-35]. For the purpose of reporting 
throughout the manuscript, results are reported for analyses treating all studies as 
independent, while corresponding dependent meta-analyses are reported in Appendix 
Results and signposted in the main text as appropriate. We investigated heterogeneity using 
forest plots and the I2 statistic and publication bias using Egger’s regression test [36] and the 
‘Trim and fill’ method [37]. For the analysis of AEs, data for all conditions were combined. 
We also examined whether estimates varied according to treatment, design, clinical 
condition and dose of study drug using meta-regression.  
 
Our primary analysis includes the results of all studies where the mean age of study 
participants was ≥50 years. As many participants in these included studies were <50 years 
of age, we also carried out separate analyses restricted to studies where all participants 
were ³ 50 years of age and also where all participants were ³ 65 years of age. These 
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analyses were carried out where there were at least 2 studies with analysable data. 
Statistical analyses were performed using the metafor package in R (version 3.6.3) [38]. For 
meta-analysis of dependent effect-sizes with robust variance estimation we also used the 




Figure 1 (PRISMA flow chart) summarizes the study selection procedure. Main 
characteristics and outcome measures of each study are included in Table 1A, 1B and 1C; 
additional details regarding studies are presented in Results in S2 Appendix and Tables 2a-b 
in S2 Appendix. A total of 60 comparisons of CBM and control intervention using RCT 
design (hereafter called RCTs) (n= 6216 participants; 1933.47person-years of cannabinoid 
exposure) from 46 published articles were included (Figure 1). Of these, 4 RCTs recruited 
participants over age ≥ 65 years (n=68; mean age, 72.4 (SD± 4.5)), of which one was ≥ 75 


















































***Ahmed et al. 
2014, 
(Netherlands) 
Crossover  12/11 
72.00 (5), 50 
12/11 
72.00 (5), 50 
≥65 years 
 
Healthy older subjects Namisol Placebo .4 6.5mg Moderate 




77.30 (5.6), 70 
10/10 
77.30 (5.6), 70 
≥18 years 
 
Dementia Namisol Placebo 2.6 3 mg Moderate 






67.00 (10.9), 64 
22/10 
65.50 (8), 50 
Adult 
 
Cancer patients with 
chemosensory alterations 
Dronabinol Placebo 2.6 7.5 mg Low 





52.70 (7.7), 76 
25/25 
58.80 (6.1), 72 
21-65 years 
 
Obstructive Sleep Apnoea Dronabinol Placebo 6.0 2.5 mg Low 





54.70 (7), 67 
25/25 
58.80 (6.1), 72 
21-65 years 
 
Obstructive Sleep Apnoea Dronabinol Placebo 6.0 10 mg Low 
Curtis et al. 2009 
(UK) 
Crossover 44/37 
52.00 (9.5), 50 
44/37 
52.00 (9.5), 50 
≥18 years 
 
Huntington’s disease Nabilone Placebo 5.0 2 mg Low 




52.00 (NR), 62 
25/24 




Chronic pancreatitis Namisol Diazepam .1 8 mg Moderate 
**Herrmann et 
al. 2019, (Canada) 
Crossover 39/38 
87.00 (10), 77 
39/38 
87.00 (10), 77 
≥55 years 
 
Alzheimer’s disease Nabilone Placebo 6.0 1.6 mg Moderate 





67.00 (10), 66 
159/159 
65.00 (11), 65 
≥18 years 
 
Cancer-related anorexia Dronabinol Megestrol 
acetate 
8.1 5 mg Low 







61.30 (12.5), 52 
59/59 







Placebo 2.0 23 mg Moderate 





47.0 (20-68) *,† 
48 
21/21 





nausea and vomiting 
Dronabinol Prochlorperaz
ine 
.9 40 mg Low 





61.60 (14.2), 53 
14/14 




nausea and vomiting 
Dronabinol Placebo .7 20 mg Low 





65.4 (7.94), 53 
19/19 
64.0 (8.04), 74 
≥30 years 
 
Parkinson’s disease Nabilone Placebo 4.0 0.75 mg Moderate 
Sieradzan et al. 
2001(UK) 
Crossover 9/9 
59.00 (NR), 44 
9/9 
59.00 (NR), 44 
NR 
 
Parkinson’s disease Nabilone Placebo .1 2 mg Very low 





60.00 (12), 54 
48/48 
62.00 (10), 52 
Adult 
 








50.0 (NR), 42 
24/24 
50.0 (NR), 42 
18-55 years 
 
Multiple sclerosis Dronabinol Placebo 3.0 10 mg Moderate 




55.30 (5), 100 
6/6 
55.30 (5), 100 
NR 
 
Intraocular pressure THC extract 
spray  
Placebo .1 5 mg Low 





60.80 (15.3), 38 
13/13 





Nabilone Placebo 5.0 4 mg Low 
Van Amerongen 
et al. 2017, 2 
(Netherlands) || 
Crossover 24/24 
54.30 (8.9), 33 
24/24 
54.30 (8.9), 33 
≥18 years 
 
Multiple sclerosis THC Placebo .1 16 mg Moderate 
Van Amerongen 





57.30 (9), 33 
12/12 
51.40 (8), 33 
≥18 years 
 
Multiple sclerosis THC Placebo 4.0 28.5 mg Moderate 
Van den Elsen et 





79.00 (8), 46 
26/26 
78.00 (7), 54 
≥40 years 
 
Dementia  Namisol Placebo 3.0 4.5 mg Moderate 
Van den Elsen et 
al. 2015, 2 
(Netherlands) 
Crossover 22/22 
76.40 (5.3), 68 
22/22 
76.40 (5.3), 68 
≥18 years 
 
Dementia  Namisol Placebo 2.6 3 mg Moderate 




72.70 (4.9), 92 
15/12 
72.70 (4.9), 92 
NR 
 
Alzheimer’s disease Dronabinol Placebo 6.0 5 mg Very low 




78.00 (NR), 100 
2/2 
78.00 (NR), 100 
NR 
 
Alzheimer’s disease Dronabinol Placebo 2.0 2.5 mg Very low 
Ware et al. 2010 
(Canada) 
Crossover 32/32 
50.00 (11.2), 16 
32/32 
50.00 (11.2), 16 
≥18 years Fibromyalgia Nabilone Amitriptyline 2.0 1 mg Moderate 
Weber et al. 2010 
(Switzerland) 
Crossover 27/22 
57.00 (12), 74 
27/22 




sclerosis patients with 
cramps 
Dronabinol Placebo 2.0 10 mg Moderate 




60.00 (7), 0 
9/9 
60.00 (7), 0 
18-75 
 
Cervical dystonia Dronabinol Placebo 3.0 15 mg Low 





50.00 (8.2), 31 
222/213 
51.00 (7.6), 37 
18-64 
 
Multiple sclerosis Dronabinol Placebo 14.0 25mg Moderate 





50.00 (8.2), 31 
120/120 
51.00 (7.6), 37 
18-64 
 
Multiple sclerosis Dronabinol Placebo 52.0 25 mg Moderate 





52.30 (7.6), 40 
166/164 
52.00 (8.2), 41 
18-65 
 







































60.9 (10.6), 26 
27/27 









































50 (41-70) * 
0 
9/9 























61.4 (10.9), 61 
103103 



















60.0 (11), 53 
199/198 


















59.0 (8.8), 55 
14/14 
59.0 (7.7), 50 
≥18 years Type 2 
diabetes 









58.0 (8.1), 75 
14/14 















59.4 (12.1), 55 
59/59 





















59.2 (12), 56 
198/198 


















56.0 (10.8), 17 
18/16 































Placebo 12.0 19.7mg THC: 
































52.4 (15.8), 44 
62/62 

















67.0 (NR), 50 
 
5/4 
















58.0 (NR), 80 
6/5 


















59.0 (12.3), 49 
91/91 


















59.0 (13.1), 56 
91/91 






















58.0 (11.2), 53 
91/91 









Placebo 5.0 43.2mg THC: 
40mg CBD 
Moderate 



























57.6 (14.4), 34 
118/118 


















61.0 (12), 56 
48/48 
















55.0 (10), 49 
57/50 
















51.0 (9.4), 41 
80/80 
















51.0 (7.6), 36 
222/213 
















51.0 (7.6), 36 
120/120 

















51.9 (7.7), 39 
135/134 
























Mean age (SD) 




















Consroe et al. 
1991, USA 
Crossover 18/15 
47.82 (15.3), 53 
18/15 
47.82 (15.3), 53 
NR Huntington's 
Disease 
CBD  Placebo 6 700mg Low 














CBD Placebo 13 200mg Moderate 




55.3 (5.0), 100 
6/6 
55.3 (5.0), 100 
NR Intraocular 
pressure 
CBD Placebo 0.1 20mg Low 




55.3 (5.0), 100 
6/6 
55.3 (5.0), 100 
NR Intraocular 
pressure 
CBD Placebo 0.1 40mg Low 
 
*, Median age (range); †, Included as median age for whole study population was ≥50; ‡, Article included more than one dose level; §, Article included more than one 
cannabinoid intervention; || , Article included the results of multiple trials; ¶, Article included multiple study groups/indications ; NR, Not recorded  







The formulations used in THC studies were (numbers within brackets indicating the number 
of RCTs where each formulation was used): nabilone (6), dronabinol (marinol) (14), THC (3), 
THC extract spray (2) and Namisol (5). The combination THC:CBD trials used THC:CBD 
spray (18), cannabis extract (6) and CBD/THCV (2). The CBD studies used CBD 
preparations only. 
 
The disease conditions investigated were classified into broader subgroups for analysis 
purpose as neurodegenerative (Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease. Amyotrophic lateral sclerosis), multiple sclerosis, motor neuron disease, pain 
(neuropathic pain), cancer (cancer or chemotherapy related anorexia, pain or 
nausea/vomiting), other (type 2 diabetes mellitus, chronic obstructive pulmonary disease, 
fibromyalgia, raised intraocular pressure, cervical dystonia, healthy, pancreatitis, obstructive 
sleep apnoea and Levodopa induced dyskinesia in Parkinson’s disease). 
 
Figures 2 (A-F), figures 3 (A-F) and Figure 4A show the forest-plots and summary results of 
the meta-analyses stratified according to study design, for all cause and treatment-related 










Figure 2A. Forest Plot of all cause Adverse Events: THC studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 










Figure 2B. Forest Plot of treatment-related Adverse Events: THC studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 











Figure 2C. Forest Plot of all cause Serious Adverse Events: THC studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 











Figure 2D. Forest Plot of treatment-related Serious Adverse Events: THC studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 











Figure 2E. Forest Plot of Adverse Event-related Withdrawals: THC studies. 
Numbers under the ‘Mean Age (yrs)’ and ‘Withdrawals (n)’ columns refer to the values in 
active and control intervention arms respectively. 
 
The conditions listed are the disease conditions sub-grouped into broader categories for 
meta-regression analyses purposes. They are: Neurodegenerative disorders (ND) 
(dementia, Alzheimer’s disease, Parkinson’s disease (PD), Huntington’s disease, 
Amyotrophic lateral sclerosis); Multiple sclerosis (MS); Cancer (cancer or chemotherapy 
related anorexia, pain or nausea/vomiting, chemosensory alterations); and Other (type 2 
diabetes mellitus, fibromyalgia, raised intraocular pressure, cervical dystonia, healthy, 






Figure 2F. Forest Plot of all deaths: THC studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 
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Figure 3A. Forest Plot of all cause Adverse Events: THC:CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 














Figure 3B. Forest Plot of treatment-related Adverse Events: THC:CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 














Figure 3C. Forest Plot of all cause Serious Adverse Events: THC:CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 














Figure 3D. Forest Plot of treatment-related Serious Adverse Events: THC:CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 














Figure 3E. Forest Plot of all Withdrawals: THC:CBD studies. 
Numbers under the ‘Mean Age (yrs)’ and ‘Withdrawals (n)’ columns refer to the values in 
active and control intervention arms respectively. 
 
The conditions listed are the disease conditions sub-grouped for meta-regression analyses 
purposes are: Multiple sclerosis (MS); motor neuron disease (MND); pain (neuropathic pain, 
rheumatoid arthritis), cancer (cancer or chemotherapy related anorexia, pain or 
nausea/vomiting), diabetes mellitus, chronic obstructive pulmonary disease (COPD), healthy 








Figure 3F. Forest Plot of all deaths: THC:CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 















Figure 4A. Forest Plot of all cause Adverse Events: CBD studies. 
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and 














Overall study quality GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) [31] is reported in Table 1 a-c, and Results in S2 Appendix. Risk of bias 




















































Figure 2G. Risk of bias (THC studies). 






Figure 2H. Summary of risk of bias (THC studies). 














Figure 3G. Risk of bias (THC:CBD studies). 




Figure 3H. Summary of risk of bias (THC:CBD studies). 















Figure 4B. Risk of bias (CBD studies). 





A total of 30 RCTs (15 crossover and 15 parallel-arm) from 29 articles[39-41,43-67] (see 
Results in S2 Appendix and Table 2a in S2 Appendix, for additional details), reported on 
1461patients on active [analysed1417; Total person-years of THC exposure: 1252.83 
person-years; Mean person-years of THC exposure (mean± SD): 41.76±184.28 person-
years] and 1251 (analysed 1210) patients on control intervention, ranging from 50-87 years 
in mean age (males: 0-100%). All except four studies used placebo control [43,45,54,62].  
 
Pooled IRRs for all cause (k=21) and treatment-related AEs (k=9) from all RCTs were 1.42 
(95% CI,1.12 -1.79) and 1.60 (95% CI, 1.26 -2.04) respectively. Pooled IRRs for all cause 
(k=27) and treatment related (k=23) SAEs from all RCTs were 1.08 (95% CI, 0.80 -1.46) and 
1.23 (95% CI, 0.56 -2.69) respectively. Pooled RR for AE-related withdrawals (k=27) and 
IRR for all deaths (k=30) from all RCTs were 1.18 (95% CI,0.89 -1.57) and 1.09 (95% 
CI,0.75 -1.59) respectively. Neither Egger’s test nor ‘Trim and fill’ method indicated 
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publication or other selection bias for any of the outcomes except for SAEs (Results in S2 
Appendix and Figure 4A-F in S2 Appendix). For all cause SAEs, while Egger’s test was non-
significant, Trim-fill-method identified 10 missing studies. The estimated effect of treatment 
on IRR for all cause SAEs, which was not significant previously, became significant after 
inclusion of potentially missing studies identified by the trim-fill-method (1.46, 95% CI:1.09- 
1.95; p=0.01, k=35). For treatment-related SAEs, Egger’s test indicated significant 
publication bias and Trim-fill-method identified 5 missing studies, though they did not change 
the direction or significance of effect-size on inclusion. Where there was non-independence 
of outcome data used in analyses, results of dependent meta-analyses were consistent with 
the results of independent meta-analyses (Results in S2 Appendix).  
 
Effect of moderators:  
Meta-regression analyses indicate that there was a trend-level effect [QM(df=4)=9.986, p= 
0.084] of clinical condition on estimated effect of THC treatment on all cause AEs, which 
seemed to be mainly related to a significantly lower estimated effect in RCTs investigating 
neurodegenerative disorder (regression coefficient=0.905; p=0.006) patients compared to 
other conditions. Except that, moderators such as study design or type of intervention did not 
significantly influence estimated effects of THC treatment on any of the outcomes assessed.  
 
Effect of dose:  
Meta-regression analyses also indicated that there was a significant effect of daily THC dose 
on all cause AEs [QM (df= 1)= 5.024, p=0.025] as well as  on AE-related withdrawals [QM 
(df= 1)= 4.696, p=0.03] for all RCTs indicating that higher the dose of THC the higher was 
the risk of all cause AEs and risk of withdrawal (regression coefficient = -0.905; p=0.006) 
from study in THC-treated patients compared to control treatment (Figure 1 in S2 Appendix). 
There was no significant association of daily THC dose with any of the other estimates 




Common side effects:  
Pooled IRRs of the most commonly reported AEs (Table 3a in S2 Appendix) suggested 
significantly higher incidence rate of dry mouth, dizziness/light-headedness, 
mobility/balance/coordination difficulties, somnolence/drowsiness, euphoria and male 
impotence in active compared to control arms. 
 
Analysis of studies where all participants were ≥50 years:  
Restricting the meta-analysis to the four studies [39-41,65] that recruited participants with 
≥50 years of age (total n=136; analysed n=126), results were broadly comparable to the 
primary analysis in the pattern of findings, though effect on all cause AEs was no longer 
significant. The pooled IRRs for all cause AEs (k=3) was 2.13 (95% CI, 0.46 -9.97) and 
treatment-related AEs (k=3) was 2.80 (95% CI, 1.09 -7.21) respectively. Pooled IRRs for all 
cause (k=4) and treatment related SAEs (k=2) were 1.20 (95% CI, 0.39 -3.65) and 0.50 
(95% CI, 0.03 -7.99) respectively. Pooled RR for AE-related withdrawals (k=4) and IRR for 
all deaths (k=4) were 1.11 (95% CI, 0.49 -2.55) and 0.58 (95% CI, 0.11 -3.06) respectively 
(Figure  8A-F in S2 Appendix). 
 
Analysis of studies where all participants were ≥65 years:  
Restricting the meta-analysis to only the three studies [39-41] that recruited participants with 
≥65 years of age (total n=58; analysed n=50), effects were also broadly comparable to the 
primary analysis in the pattern of findings, with the exception of effect on all cause AEs, 
which was no longer significant. The pooled IRRs for all cause AEs (k=3) was 2.13 (95% CI, 
0.46 -9.97) and treatment-related AEs (k=2) was 2.80 (95% CI, 1.09 -7.21) respectively. 
Pooled IRRs for all cause (k=3) and treatment related SAEs (k=2) were 1.80 (95% CI, 0.13 -
8.76) and 0.50 (95% CI, 0.03 -7.99) respectively. Pooled RR for AE-related withdrawals 





THC:CBD combination studies 
A total of 26 studies (5 crossover and 21 were parallel-arm; see Results in S2 Appendix and 
Table 2b in S2 Appendix for additional details) from 21 articles [42,46,48,49,68-85] reported 
on 1965 patients [analysed 1940; Total person-years of THC:CBD exposure: 394.29 person-
years; Mean person-years of THC exposure (mean± SD): 15.17±28.20 person-years] on 
active and 1887 (analysed 1863) on placebo, ranging from 50-67 years in age (males: 0-
80%). All studies used placebo as control. Two of the 26 included studies [81] investigated a 
combination of CBD and THCV and we also examined the key effects after excluding these 
studies, which remained unchanged (please see figures 7A-F in S2 Appendix). Results of 
meta-analysis for individual AEs after excluding these studies was identical to the results 
including all studies (as shown in Table 3b in S2 Appendix) and hence not shown. 
 
Pooled IRRs for all cause (k=16) and treatment-related (k=9) AEs from all RCTs was 1.58 
(95% CI,1.26 -1.98) and 1.70 (95% CI,1.24 -2.33) respectively. Pooled IRRs for all cause 
(k=26) and treatment-related (k=21) SAEs from all RCTs was 1.17 (95% CI,0.99 -1.39) and 
1.19 (95% CI, 0.88 -1.62) respectively. Pooled RR for AE-related withdrawals (k=26) and 
IRR for all deaths (k=26) from all RCTs were 1.40 (95% CI,1.08 -1.80) and 1.14 (95% CI, 
0.89 -1.46) respectively. Neither Egger’s test nor ‘Trim and fill’ method indicated any 
significant effect of publication or other selection bias for any of the outcomes except for 
deaths ( Figure 5A-F in S2 Appendix). For deaths as outcome, while Egger’s test was not 
significant, Trim and fill method indicated 9 missing studies, with the estimated effect 
becoming significant after their inclusion (1.33, 95% CI:1.03- 1.71; p=0.027, k=35). Where 
there was non-independence of outcome data used in analyses, results of dependent meta-
analyses were consistent with the results of independent meta-analyses.  
 
Effect of moderators:  
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Meta-regression analysis indicated that there was a significant effect of clinical condition on 
effect-size for treatment-related AEs [QM (df=3)=15.948, p= 0.01] and AE-related 
withdrawals [QM (df=3)=8.987, p= 0.029]. For treatment-related AEs, this was mainly related 
to a significantly higher effect-size in RCTs investigating pain conditions (regression 
coefficient = 0.393; p=0.022) and those investigating other conditions (regression coefficient 
= 1.263; p=002) compared to cancer conditions. For withdrawals, this was related to 
significantly higher effect-size in RCTs investigating pain conditions (regression coefficient = 
0.816; p=0.020) and multiple sclerosis (regression coefficient = 0.675; p=0.035)compared to 
cancer conditions. Except these, moderators such as study design or type of intervention did 
not significantly influence estimated effects of THC:CBD combination treatment on any of the 
outcomes assessed.  
 
Effect of dose:  
There was a significant effect of daily THC dose [QM (df=1)=4.554, p= 0.033] on AE-related 
withdrawals (Figure 2 in S2 Appendix) and a trend-level effect on all cause [QM 
(df=1)=2.899, p= 0.089] and treatment-related AEs QM (df=1)=3.016, p= 0.082].. Exploratory 
analyses suggested that there was also a significant effect of CBD dose (QM (df=1)=4.539, 
p=0.033) on all cause AEs (Figure 3 in S2 Appendix) and a trend-level effect [QM 
(df=1)=3.145, p=0.076]  on treatment-related AEs, but no significant effect on withdrawals. 
Effects of dose of both THC and CBD were such that the higher their dose, the higher was 
the effect of THC:CBD combination treatment on withdrawals and AEs (all cause and 
treatment-related). Except these, daily THC or CBD dose did not have any significant 
influence on the effects of THC:CBD combination treatment on SAEs or death.  
 
Common side-effects:  
Pooled IRRs of the most commonly reported AEs (Table 3b in S2 Appendix) suggested 
significantly higher incidence rate of nausea, vomiting, dry mouth, dizziness/ light-
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headedness, somnolence/drowsiness, disorientation, fatigue and visual symptoms in active 
compared to control arms.  
 
Analysis of studies where all participants were ≥50 years:  
Restricting the meta-analysis to the 3 studies [42,68] that recruited participants with ≥50 
years of age (total n= 60; analysed n=52) were similar to the primary analysis in the pattern 
of findings, except for treatment-related AEs and AE-related withdrawals, which were no 
longer significant. The pooled IRRs for all cause AEs (k=3) was 2.65 (95% CI,1.49 -4.71) 
and treatment-related AEs (k=2) was 4.73 (95% CI, 0.54 -41.65) respectively. Pooled IRRs 
for all cause (k=3) and treatment related SAEs (k=3) were 1.00 (95% CI, 0.10 -9.61) and 
1.00 (95% CI, 0.10 -9.61) respectively. Pooled RR for AE-related withdrawals (k=3) and IRR 
for all deaths (k=3) were 0.77 (95% CI, 0.18 -3.22) and 1.00 (95% CI, 0.10 -9.61) 
respectively (Figure 9A-F in S2 Appendix). None of these studies reported any SAEs (either 
treatment-related or all cause) or death. 
 
Analysis of studies where all participants were ≥65 years: 




Four studies (3 crossover and 1 parallel-arm RCT) from 3 articles [50,81,86] reported on 43 
patients (analysed 40) on active and 44 (analysed 41) on placebo, with age ranging from 53-
59 years [53-100% males; person-years of total CBD exposure: 6.60 person-years; Mean 
person-years of CBD exposure (mean± SD: 1.10±1.23 person-years)]. Pooled IRR for all 
cause AEs for all RCTs was 1.02 (95% CI,0.90 -1.16), based on data available only from the 
2 crossover studies reporting on 3 different dosage conditions (Figure 3A and Figure 6 in S2 
Appendix). There was limited data to allow quantitative synthesis of other outcomes, 
however, there were no treatment-related SAEs, withdrawals or death reported (see 
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Supplement Results, for qualitative synthesis). No analysable data was available from 
studies where all study participants were ≥50 years age. 
 
Risk of bias:  
A summary of the risk of bias of included studies are presented in the figures 2 (G,H), figures 
3 (G,H) and Figure 4B. Briefly, most RCTs reported adequate randomisation sequence 
generation and concealment, outcome objectiveness and masking of outcome assessors; 
however some studies had high risk of bias because of potential for unmasking of 
participants and study personnel and selective reporting of the safety outcome. Most studies 
reported objective outcome assessments, however only 60% of studies reported that 
outcome assessors had been appropriately blinded. 45% studies did selective reporting i.e., 
they did not report data for all the safety outcomes (AEs and SAEs) in the trial and reported 
them when they occurred more than once or were more common or when they had 
occurrence above a certain threshold (1%-10%). The authors judged 33 (55%) trials at low 
risk of bias, 20 (33%) trials at unclear risk of bias and seven (12%) trials to have high risk of 
bias for safety outcome reporting (figures 2 G-H, figure 3 G-H and figure 4B ). Overall, 36 
trials were judged to be of moderate quality, of which 15 (42%) trials reported all AEs and 




In this systematic review and meta-analysis, we investigated the safety and tolerability of 
medicinal cannabinoids in older adults by pooling data from double-blind RCTs with a 
reported mean participant age of 50 years and over. We hypothesized that compared to 
control treatments all 3 categories of CBMs will be associated with a greater incidence of 
AEs, but no greater incidence of SAEs, death or risk of withdrawal from study. We also 
expected a direct relationship between the dose of THC used in THC-containing CBMs and 
the risk of adverse outcomes. We found that generally moderate to high quality evidence 
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(about 60% studies) suggests that as hypothesized, treatment with THC-containing 
medications (THC alone and THC:CBD combination) was associated on average with 
significantly higher incidence of all-cause and treatment-related AEs compared to control 
treatments. Further, consistent with our hypotheses, the average incidence rates of serious 
AEs (all-cause and treatment-related) and death were not significantly greater under CBMs 
compared to controls in studies using THC with or without CBD. However, contrary to 
expectation, significantly higher risk of withdrawal related to AEs was noted on average for 
studies using THC:CBD combination, though this was not observed in studies that used THC 
without CBD.  In contrast, generally low-quality evidence (about 67% of studies) suggests 
that CBD alone may not significantly increase the incidence rate of all-cause of AEs. 
Qualitative synthesis of data on treatment-related AEs, SAEs, deaths and withdrawals from 
study also did not suggest any increase associated with CBMs containing CBD alone. In 
terms of relationship between THC dose and adverse outcomes, as hypothesized, we found 
a direct relationship between daily THC dose and all cause AEs and AE-related withdrawals 
in THC studies and between THC dose and AE-related withdrawals in THC:CBD studies. 
Contrary to our expectations, we did not find any association between THC dose and the 
other outcomes investigated, such as SAEs and deaths. In addition, exploratory analysis 
showed that CBD dose also had a significant direct relationship with all-case AEs and a 
strong trend-level association with treatment-related AEs in RCTs using THC-CBD 
combination. 
 
Additional analyses restricted to only those studies in which all participants were ≥50 years 
of age or ≥ 65 years of age, where this was feasible, indicated a pattern of findings broadly 
comparable with the results of our main analyses including all studies. However, the effect of 
CBMs containing THC but no CBD on all cause AEs and CBMs containing THC:CBD on 
treatment-related AEs and AE-related withdrawals were no longer significant, which likely 





Collectively, our results from studies that included participants with a mean age ≥ 50 years  
may suggest that older adults are at significantly greater risk of both treatment-related and 
all cause AEs from CBMs containing THC, but not using CBMs without THC. Despite the 
greater risk of AEs, older adults receiving CBMs do not seem to be at a significantly greater 
risk of more serious consequences such as SAEs or death. Greater risk of withdrawal from 
study in those receiving CBMs containing THC:CBD combination but not in those containing 
THC or CBD without the other cannabinoid is an unexpected finding. While we did not 
compare these two effects in a systematic manner, if true, this may suggest that combination 
of these cannabinoids may be less acceptable in this age group, who already may be 
receiving multiple treatments for comorbidities. What may underlie these effects is much less 
clear. One may speculate that this may be a result of the generally higher THC dose 
employed in THC:CBD studies compared to the THC studies, which may have made 
participants in the former group of studies more susceptible to AEs and withdrawal as a 
result compared to those receiving THC. This is supported by approximately double the 
median dose of THC used in THC:CBD studies [median and interquartile range: 10.3(10.2- 
21.6) mg/ day in crossover and 20.8(14.6-25) mg/ day in parallel-arm RCTs] as opposed to 
THC studies [median and interquartile range: 5(2.25-9 mg/ day in crossover and 10(4.8-25) 
mg/ day in parallel-arm RCTs]. In accordance with this hypothesis, there was a nominally 
higher incidence of AEs in general in those studies using both cannabinoids in combination 
compared to THC studies. However, one cannot completely rule out the possibility that 
greater risk of withdrawal from study in those receiving CBMs containing THC:CBD 
combination but not in those containing THC or CBD without the other cannabinoid, as 
observed here, is purely by chance. Further, THC dose was significantly associated with 
withdrawal in both study groups using THC-containing medications. In contrast, CBD dose 
was only associated with AEs but not withdrawal in those using THC:CBD combination. 
However, whether these results suggest that lower acceptability of THC:CBD combination is 
a tolerability issue in older patients because of combination of cannabinoids rather than 
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being related to the dose of CBD, remains to be formally tested. It is also worth noting that 
the evidence base of studies that used CBMs without THC in older adults and found it to be 
well-tolerated is relatively sparse. Whether this may underlie the absence of significantly 
greater risk of all cause AEs as a result of treatment with CBMs without THC compared to 
controls, contrary to our expectation, remains to be tested. However, more generally, lack of 
significant AEs associated with CBD treatment alone in the present study is consistent with 
other analyses suggesting a good tolerability profile of CBD alone in younger age groups 
[87,88]. Nevertheless, collectively these results suggest that although the incidence of side-
effects is greater with THC-containing products, CBMs investigated in these studies are 
generally safe. Their overall tolerability profile also seems to be generally acceptable to 
patients, though combination of THC and CBD may be less so. It is important to note that 
although the general pattern of results of analyses restricted to studies where all participants 
were ≥50 years of age or ≥ 65 years of age were broadly comparable with results from our 
main analyses of studies with mean participant age ≥50 years, they were not identical, 
indicating that effects of CBMs may be different when focused exclusively on adults over 65 
or 75 years of age.  
 
Although we did observe a significant association between THC dose and all cause AEs in 
THC studies, this was not present in THC:CBD studies. Whether this reflects independent 
evidence that CBD may mitigate some of the adverse effects of THC, such as on cognition, 
behaviour, autonomic and cardiovascular function [15,25-28] and therefore may have 
obscured any dose-response relationship with AEs in THC:CBD studies remains unclear. 
The present study was not designed to formally test this hypothesis, which needs 
independent examination.    
 
Finally, we identified a number of specific AEs associated with CBMs containing THC:CBD 
combination or THC without CBD. Of the specific AEs, significantly increased incidence of 
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dizziness/ light headedness, drowsiness, disorientation and impaired mobility/ 
balance/coordination is worth noting, in light of higher risk of falls in this age group, which 
may be further exacerbated by these treatments [89,90]. 
 
Pooled estimates of all cause AEs under both THC and THC:CBD and of treatment-related 
AEs and AE-related withdrawals under THC:CBD as reported herein need to be considered 
carefully in light of high-levels of heterogeneity (discussed further below) in the studies as 
evident from the estimated I2 statistic (>32% in all these estimates). Therefore, we have also 
reported the prediction intervals along with the 95% confidence intervals in the forest plots 
for the key pooled estimates reported herein. These prediction intervals indicate that while 
the average effects of CBM treatments on these outcomes are significant (as evident from 
the 95% confidence intervals), the range of predicted effects across different study settings 
that may be observed in a new study may span a wider range of effect sizes than indicated 
by the 95% confidence intervals. Some of these predicted effect-sizes in new studies are 
likely to be <1 indicating that the risk of these outcomes with THC or THC:CBD treatment 
may not be higher than under control treatment condition. 
 
Previous reviews of adverse consequences of treatment with CBMs have either  
been qualitative [12,19,20], did not specifically focus on older adults [16,17] or did not 
consider the effects of THC, CBD or their combination separately [12,16,17]. Even in studies 
that have pooled the adverse event data quantitatively, this has been done based on specific 
formulation rather than on the basis of their cannabinoid content [16,17]. Further, they have 
generally reported summary effect-size estimates (such as odds ratio) that do not take into 
account person-years of treatment, an important consideration in quantitative synthesis of 
outcomes from RCTs [16,17]. As in previous reviews, we found that not all studies have 
published all the AEs and SAEs and that there is lack of evidence of the safety, tolerability 
and acceptability specifically in older patients. Nevertheless, our findings are consistent with 
previous reviews which found dizziness to be the most common non-serious AE with CBM 
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treatment [12,16,17]. These results are also consistent with a prospective observational 
study of 901 people above 65 years of age (74.5 ± 7.5 years), who received medical 
cannabis from January 2015 to October 2017 in a specialized medical cannabis clinic, 
31.7% reported at least one AE due to the treatment after six months, with dizziness (9.7%) 
and dry mouth (7.1%) as the commonest AEs [21]. Another similar study of 184 people (81.2 
± 7.5 years of age) from April 2017 to October 2018 showed 33.6% with AEs and dizziness 
(12.1%) and sleepiness and fatigue (11.2%) as the commonest AEs [91]. A previous 
systematic review of the efficacy and safety of medicinal cannabinoids which focused only 
on older people considered 5 controlled trials with THC (n = 3) and oral THC:CBD (n = 2) 
[12]. However, this review did not provide summary estimates (effect sizes) due to high 
heterogeneity among the included studies, lack of available data on means and standard 
deviations per treatment group, and very small sample sizes [12]. Therefore, only qualitative 
and descriptive summaries were provided. Studies included in this review reported 
dizziness, euphoria, drowsiness, confusion, and disorientation as the common adverse 
effects [12], consistent with our report. An earlier systematic review of AEs of medicinal 
cannabinoids for all ages by Wang et al [17] included 23 RCTs published between 1966 and 
late 2007, and analysed the effect of oral THC, and THC:CBD oral and spray formulations. 
However, they did not include data from studies examining the synthetic cannabinoid 
nabilone and found no evidence of higher incidence of SAEs after a median of 2 weeks use 
compared with a control group, regardless of the age of individuals (RR 1.04, 95% CI 0.78 -
1.30). Wang and colleagues [17] reported that respiratory, gastrointestinal and nervous 
system disorders were the most frequently reported categories of SAEs and dizziness was 
the most commonly reported nonserious AE (15.5%) among people exposed to 
cannabinoids. However, unlike the present review wherein we have used GRADE criteria to 
assess methodological quality of included RCTs, Wang et al used a scale reported in a 
manuscript by Jadad and colleagues [92] to assess methodological quality of RCTs. As the 
scale from Jadad and colleagues does not adequately assess the quality of safety reporting 
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in RCTs, most studies were  rated as of good quality in the review by Wang et al, despite 
their poor reporting of safety [17].  
 
However, our results are not consistent with a more recent systematic review and meta-
analysis by Whiting et al [16], which included studies investigating all age groups and 
showed that SAEs and AE-related withdrawal are generally higher in those treated with 
CBMs. In contrast, we have shown that SAEs are not increased in older adults consistent 
with other reviews [12,17]. Whiting et al [16] found pooled effect-size for any AE (OR 
3.03,95% CI 2.42-3.80), SAE (OR 1.41, 95% CI 1.04-1.92) and withdrawal due to AE (OR 
2.94, 95% CI 2.18-3.96) and Wang et al [17] found significantly higher non-serious AEs (RR 
1.86, 95% CI 1.57-2.21) in those who received CBMs compared to control groups. In 
contrast to Whiting et al, we have shown that increase in withdrawal may be more nuanced 
and more in those receiving THC:CBD combination and not for other types of CBMs. 
 
It is difficult to compare our pooled effect-size with previous reviews due to a number of 
reasons. Firstly, Whiting reported odds ratios and Wang et al reported relative risk, wherein 
we have reported IRR. In the present context, the risk of AEs or SAEs in either study arm 
are unlikely to be constant over time. Therefore, IRR which takes into consideration person-
years of treatment and is a ratio of the incidence rate in the experimental treatment group to 
that in the control treatment group, is more meaningful and appropriate in contrast to the 
odds ratio, which is a ratio of the odds of an event in the experimental group to that in the 
control group and are not easily interpretable. Secondly, we carried out a pooled analysis for 
individual interventions unlike the other reviews, with Wang et al also excluding studies using 
Nabilone [17]. Finally, the 2 previous reviews that reported summary estimates included all 
age groups and were not specific for older people unlike here. 
 
Our results extend previous literature by showing that although at significantly higher risk of 
adverse events from CBMs containing THC, but not from those without THC, CBMs are 
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generally safe in older adults, who typically experience co-morbid health conditions[93] and 
receive polypharmacy [94]. Also, CBMs are generally acceptable as long as they are not a 
combination of THC and CBD.  
 
Results presented here may also need to be considered against the side-effect profile of 
common treatments for the clinical conditions investigated in studies included in the meta-
analyses reported here, as safety and tolerability profile of a potential new treatment relative 
to existing alternatives is an important consideration in the context of prescribing. Studies 
included patients with Alzheimer’s disease, Parkinson’s disease, Huntington’s disease. 
Amyotrophic lateral sclerosis, multiple sclerosis, motor neuron disease, neuropathic pain, 
cancer (cancer or chemotherapy related anorexia, pain or nausea/vomiting), type 2 diabetes 
mellitus, chronic obstructive pulmonary disease, fibromyalgia, raised intraocular pressure, 
cervical dystonia, pancreatitis and obstructive sleep apnoea. As would be expected, these 
conditions are typically treated with a wide range of pharmacological treatments (opioid 
analgesics, non-steroidal anti-inflammatory, anti-epileptics, benzodiazepines, psychotropics, 
cholinesterase inhibitors, glutamate antagonists, dopamine agonists, immunosuppressants, 
muscle relaxants, etc) with a varied side-effect profile. While a systematic comparison of 
side-effect profile of CBMs and these other treatments would be useful and can helpfully 
inform prescribing decisions, this was outside the scope of the present review and was not 
examined here. Therefore, future studies may need to investigate this in a systematic 
manner. As we pooled data from randomized controlled comparisons, as opposed to 
observational studies without a control arm, they are very unlikely to have confounded the 
results presented herein. 
 
Strengths and limitations 
Our review and meta-analysis are limited by a number of methodological weaknesses some 
of which stem from the design and analytic approach of the present study and others which 
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are related to weaknesses in the studies that were included in the present analysis. One of 
the key limitations inherent in the meta-analytic approach that also applies to the present 
study relates to the issue of heterogeneity in the pooled data [95]. Studies pooled in our 
analyses focused on patients with different clinical conditions and indications, used different 
doses, formulations and routes of administration of the study drug for different treatment 
periods and employed different study designs (cross-over versus parallel-arm RCTs). 
Further, although we attempted to control for patients from widely disparate age groups 
taking part in the trial by setting an inclusion criterion of mean age of 50 years and over as 
the cut-off, studies included in our main analyses still involved data from people below age 
50 and studies also varied in terms of sex distribution. This is reflected in the heterogeneity 
estimates reported in our results. In order to address this wide-ranging heterogeneity and yet 
pool the data in a meaningful way, we employed a random-effects model in our analyses, 
which assumes that there will be variability in the observed estimates of treatment effects 
across studies, both as a result of real differences in the effect of treatment between studies 
as well as by chance because of sampling variability. As a result, pooled estimates reported 
are not precise (as may be evident from the wide confidence intervals) and should not be 
considered as such. Effects reported here represent an average effect of CBM treatments on 
safety and tolerability outcomes investigated rather than an effect that is common across 
studies. As the effects may be different within an individual study, we also report a prediction 
interval for our key reported outcomes, in order to give an estimate of the range of predicted 
effects across study settings that may be observed in a new study. Further, we also carried 
out sub-group (e.g. cross-over and parallel-arm RCTs separately) and meta-regression 
analyses to examine the sources of heterogeneity for THC and THC:CBD studies. These 
analyses did not suggest that study design or type of intervention had any significant effect 
on the outcomes assessed, though they suggest that effects vary, sometimes significantly, 
across clinical conditions investigated in the RCTs. They were more pronounced in AE-
related withdrawals and treatment-related AEs in THC:CBD studies and less so for all cause 
AEs in studies investigating THC as a treatment. Dose of study drug also seemed to underlie 
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some of the heterogeneity observed in all cause and treatment-related AEs and AE-related 
withdrawals in the THC and THC:CBD studies. Another limitation relates to the fact that we 
were not able to systematically examine the sources of heterogeneity for CBD alone studies 
as there were fewer studies than recommended for such analyses. One other limitation of 
the present meta-analysis relates to our focus on studies reporting on participants aged 50 
years and over.  
 
Further, we included studies in which the mean age of study participants was ≥50 years 
(although the studies also included many participants who were <50 years of age). As the 
cut-off employed by us differs from the conventional threshold of 65 years for ‘elderly’ [96], 
this may be considered as a limitation. However, this was chosen as the clinical conditions 
(diabetes, cancer, neurodegenerative disorders, cancer etc) for which CBMs are often 
considered become more common from around this age. This is also a period characterised 
by multi-morbidities, polypharmacy and age-related bodily changes that may affect 
pharmacokinetics [96] and tolerability of medications. Further, in order to address the 
limitation that many participants in the included studies were <50 years of age, we also 
carried out sensitivity analysis that included studies where all participants were ³ 50 years of 
age.  The results of these analyses suggest that the pooled effect-sizes were generally in the 
same direction as that reported from the larger set of studies, though the confidence 
intervals were wider, as may be expected.  We have also reported the number of studies 
which have actually studied individuals with age ³ 65 years or ³ 75 years. As evident from 
this, there is a very limited set of studies that have exclusively focused on people at these 
ages. Therefore, the present meta-analysis highlights the need for studies that may need to 
focus on people over 65. However, given the age range as well as median and interquartile 
range of the mean ages of study participants included in the studies that constitute our meta-
analysis, it is clear that people over 65 and 75 years are currently being recruited into 
studies of CBMs for various indications. As individual RCTs are often not powerful enough to 
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unravel patterns of side-effects and given the growing use of CBMs in the elderly and 
general perception of them being safe, it is particularly important to summarize currently 
available evidence to help inform about the safety and tolerability profile of CBMs in those 
aged 50 years and over rather than wait for the evidence base focusing only on ³ 65 years 
to mature. In the fullness of time, future attempts at evidence synthesis need to focus only 
on studies of people ³ 65 years when a sufficient number of studies have accumulated. 
 
The other main source of limitation stems from methodological limitations in the included 
trials as identified during quality assessment [30,31], specifically pertaining to selective 
outcome reporting, and inadequate description of methods of randomization, allocation 
concealment, and blinding. Additionally, many included RCTs investigated only modestly 
sized samples  [41,42,44,50,57]. Small samples render studies particularly underpowered 
when estimating serious and less serious adverse outcomes, which by their nature may not 
occur frequently. It is in this context, that the present report addresses an important gap in 
extant evidence by systematic quantitative synthesis of RCT data following existing 
recommendations [30,31] to provide estimates from a larger pool of patients. Further, our 
analyses suggest that publication or other selection biases are unlikely to have influenced 
the pooled estimates reported here.   
 
Unlike in previous meta-analyses, which reported summary effects separately based on 
indications, we pooled safety and tolerability data in older adults across a broad range of 
indications. While this may have added to the heterogeneity of the data synthesized, it 
allowed us to comprehensively estimate separately the effects of three broad categories of 
cannabinoid-based interventions i.e., THC only, THC:CBD combination and CBD only, 
something that has not been done before. This is a key strength of the present approach, 
given the reported opposite effects of different cannabinoids [4,15] that argue against data 
being combined. Another important strength of the present report relates to the analysis of 
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the effects of moderators to examine the extent to which they may have influenced results, in 
particular relationship with cannabinoid doses used.  
 
Studies evaluated various routes of CBM administration (oral capsules, tablets, sublingual 
spray, oromucosal spray).  Also, not all studies compared CBMs with placebo, with four 
studies using active control treatments  [43,45,54,62]. While all of these may have resulted in 
a very heterogeneous set of included studies, we used a random-effects model to mitigate 
these effects. Further, heterogeneity did not seem to significantly affect any of our estimates 
other than all cause AEs, giving further confidence in the results reported. Nevertheless, we 
have also reported prediction intervals in addition for our key reported outcomes to give an 
estimate of the range of predicted effects across different study settings. Finally, another 
important potential limitation of the present study relates to the fact that we did not 
investigate the efficacy of CBMs in older adults. As outcome measures used to index 
efficacy vary widely between clinical conditions and there is a relative paucity of studies 
investigating a particular clinical condition, there is not enough data for any quantitative 
synthesis of efficacy of different CBMs in older adults to be meaningful just yet.    
 
Clinical efficacy is one of the foremost considerations in addition to patient choice and safety 
/ tolerability of interventions when prescribing in clinical practice. While the present study 
summarizes current evidence regarding safety / tolerability of CBMS, there is limited efficacy 
evidence for most clinical indications for which CBMS have been used in older people. 
Therefore, there is a pressing need for efficacy studies in specific indications where there is 
proof of concept or rationale for use of CBMs in older people. With regard to CBMs, potential 
for drug-drug interaction in light of effect on cytochrome p450 enzymes is a major concern in 
the context of treating older patients [13]. However, few studies have examined this, an 
important likely determinant of tolerability and dose adjustment, and therefore worthy of 




Complete reporting of safety/ tolerability data as well as improved trial designs incorporating 
robust methods for allocation concealment, masking of participant and outcome assessors 
are further important considerations for future trials. Using well-powered samples, such 
studies need to focus on safety, tolerability as well as efficacy of different categories of 
CBMs, in particular CBD on its own, a relatively less investigated CBM in older people. 
 
Conclusion 
Results of the present study using data from RCTs with mean participant age ≥ 50 years 
suggest that although THC-containing CBMs are associated with side-effects in those aged 
50 years and over, in general CBMs are safe and acceptable treatments in older adults, with 
a caveat that THC:CBD combinations may be less so at least in dose ranges used in studies 
thus far. However, tolerability may be different in adults over 65 or 75 years of age, and 
robust evidence of efficacy of different CBMs for specific indications is needed before they 
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Supporting Information (S2 Appendix) Captions: 
 
Figure 1. THC dose related withdrawals in THC studies 
 
Figure 2. THC dose related withdrawals in THC:CBD studies  
 
Figure 3. CBD dose related all cause AEs in THC:CBD studies  
 
Figure 4: Funnel plots for all tolerability and safety outcomes: THC studies  
a. All cause Adverse Events (AEs); b. Treatment-related AEs; c. All cause Serious Adverse Events 
(AAEs); d. Treatment-related SAEs; e. AE-related Withdrawals; f. Deaths. 
 
Figure 5: Funnel plots for all tolerability and safety outcomes: THC:CBD studies  
a. All cause Adverse Events (AEs); b. Treatment-related AEs; c. All cause Serious Adverse Events 
(AAEs); d. Treatment-related SAEs; e. AE-related Withdrawals; f. Deaths. 
  
Figure 6: Funnel plot for all cause Adverse Events (AEs): CBD studies   
 
Figure 7A. Forest Plot of all cause Adverse Events: THC:CBD studies (excluding THCV).  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 





Figure 7B. Forest Plot of treatment-related Adverse Events: THC:CBD studies (excluding 
THCV).  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
 
Figure 7C. Forest Plot of all cause Serious Adverse Events: THC:CBD studies. (excluding 
THCV).  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
  
Figure 7D. Forest Plot of treatment-related Serious Adverse Events: THC:CBD studies 
(excluding THCV).  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
  
Figure 7E. Forest Plot of all Withdrawals: THC:CBD studies (excluding THCV).  
Numbers under the ‘Mean Age (yrs)’ and ‘Withdrawals (n)’ columns refer to the values in active and 
control intervention arms respectively.  
The conditions listed are the disease conditions sub-grouped for meta-regression analyses purposes 
are: Multiple sclerosis (MS); motor neuron disease (MND); pain (neuropathic pain, rheumatoid 
arthritis), cancer (cancer or chemotherapy related anorexia, pain or nausea/vomiting), diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), healthy controls (HC), levodopa induced 





Figure 7F. Forest Plot of all deaths: THC:CBD studies (excluding THCV).  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
 
Figure 8A. Forest Plot of all cause Adverse Events: THC studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively.   
Figure 8B. Forest Plot of treatment-related Serious Adverse Events: THC studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively.   
 
Figure 8C. Forest Plot of all cause Serious Adverse Events: THC studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively.   
 
Figure 8D. Forest Plot of treatment-related Serious Adverse Events: THC studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively.   
 
Figure 8E. Forest Plot of Adverse Event-related Withdrawals: THC studies.  
Numbers under the ‘Mean Age (yrs)’ and ‘Withdrawals (n)’ columns refer to the values in active and 




The conditions listed are the disease conditions sub-grouped into broader categories for meta-
regression analyses purposes. They are: Neurodegenerative disorders (ND) (dementia, Alzheimer’s 
disease, Parkinson’s disease (PD), Huntington’s disease, Amyotrophic lateral sclerosis); Multiple 
sclerosis (MS); Cancer (cancer or chemotherapy related anorexia, pain or nausea/vomiting, 
chemosensory alterations); and Other (type 2 diabetes mellitus, fibromyalgia, raised intraocular 
pressure, cervical dystonia, healthy, pancreatitis, obstructive sleep apnoea).  
 
Figure 8F. Forest Plot of all deaths: THC studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively.   
 
Figure 9A. Forest Plot of all cause Adverse Events: THC:CBD studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
 
Figure 9B. Forest Plot of treatment-related Adverse Events: THC:CBD studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
 
Figure 9C. Forest Plot of all cause Serious Adverse Events: THC:CBD studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 





Figure 9D. Forest Plot of treatment-related Serious Adverse Events: THC:CBD studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
  
Figure 9E. Forest Plot of all Withdrawals: THC:CBD studies.  
Numbers under the ‘Mean Age (yrs)’ and ‘Withdrawals (n)’ columns refer to the values in active and 
control intervention arms respectively.  
The conditions listed are the disease conditions sub-grouped for meta-regression analyses purposes 
are: Multiple sclerosis (MS); motor neuron disease (MND); pain (neuropathic pain, rheumatoid 
arthritis), cancer (cancer or chemotherapy related anorexia, pain or nausea/vomiting), diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), healthy controls (HC), levodopa induced 
dyskinesia in Parkinson’s disease) (PD).  
 
Figure 9F. Forest Plot of all deaths: THC:CBD studies.  
Numbers under the ‘Subjects (n)’ column refer to analysed subjects from the active and control 
intervention arms respectively. CE refers to cannabis extract.  
 
